The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Patients, doctors, and caregivers come together to promote awareness, early intervention, and pain-free living
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
New home-use glucometer delivers results in under 10 seconds with simplified testing, large memory storage, and user-friendly design
Hyderabad based 400-bed facility brings AI-driven care, advanced imaging, and integrated clinical systems under one roof
The results signal shift beyond paclitaxel-coated balloon (PCB) angioplasty in femoropopliteal artery disease
_256_384.png)
The company plans a phased expansion across India, focusing initially on metro cities and early-adoption hubs
The company has supported the initiative since its inception, contributing to screening efforts in around 120 countries
Subscribe To Our Newsletter & Stay Updated
